AstraZeneca and Daiichi Sankyo: Enhertu significantly reduced the risk of disease progression in low and ultra-low HER2 metastatic breast cancer.
In patients with hormone-receptor (HR)-positive metastatic breast cancer and low or ultra-low levels of HER2 expression, Enhertu led to a ...